$XBI $127 +4%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Pipeline Updates
$CRMD -22% Plan is to be able to resubmit the defend cap NDA in the fourth quarter of 2021. source
$APLS +7% (AH) FDA approves new treatment for adults with serious rare blood disease. source
$RGNX +2% REGENXBIO PRESENTS ADDITIONAL POSITIVE INTERIM DATA FROM PHASE I/II TRIAL OF RGX-121 FOR THE TREATMENT OF MPS II (HUNTER SYNDROME) AT AMERICAN SOCIETY OF GENE AND CELL THERAPY'S 24TH ANNUAL MEETING. source
Posted by DV